Oxford BioTherapeutics in $450 deal with Wuxi Biologics
Immuncheckpoint specialist Oxford BioTherapeutics has licenced the right to develop five bispecific antibodies for combination therapies using Wuxi Biologics WuXiBody platform.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1551 entries already.
Entries by Thomas Gabrielczyk
Diabetes doubles risk for heart failure
/in News/by Thomas GabrielczykAn analysis of health records of the whole Scottish population aged ?30 years revealed that people with diabetes have an increased risk for heart failure.
AZ checkpoint blocker combo fails in head and neck cancer
/in News/by Thomas GabrielczykBritish drugmaker AstraZeneca (AZ) has missed another opportunity to secure a share in the lucrative immunoncology market: a Phase III trial combining durvalumab with tremelimumab missed the survival endpoint.
XyloCor Therapeutics bags US$17m in Series A financing
/in News/by Thomas GabrielczykLSP and Sofinnova Ventures co-led the financing of the Amsterdam-based gene therapy specialist XyloCor Therapeutics.
BioFIT: innovation and investors
/in News/by Thomas GabrielczykFor two days, Lille was the place to be for partnering in early stage innovation. On December 5th, Europe’s leading tech transfer event BioFIT wrapped up, recording a record number […]
Uncommon mutations affect breast cancer prognosis
/in News/by Thomas GabrielczykUncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications.
Argenx in US$1.6bn deal with J&J affiliate Janssen
/in News/by Thomas GabrielczykJanssen affiliate Cilag GmbH International has licenced argenx anti-CD70 antibody cusatuzumab (ARGX-110) for US$300m upfront.
Driver of GVHD after blood stem cell transplantation identified
/in News/by Thomas GabrielczykSwiss, French and German researchers have unraveled a molecular pathway that might be useful to prevent Graft-versus-Host Disease (GVHD) in leukemic recipients of blood stem cell transplants.
Investors pool 27m for new Proteomics tech
/in News/by Thomas GabrielczykUK-based biotech startup Fluidic Analytics has raised 27m for its proteomics platform. The financing round was led by Draper Esprit, with participation from Delin Ventures, BGF, IQ Capital, and Amadeus […]
Carbios set to build closed-loop PET plant
/in News/by Thomas GabrielczykFrench Carbios SA has signed a letter of intent with PVC giant Kem One to implement a demonstration plant to provide proof of concept of Carbios groundbreaking enzymatic PET depolymerisation […]